Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery

International Immunopharmacology

Volumn 9, Issue 10, 2009, Pages 1197-1208

  Bhat, Ajaz A ^a   Seth, Ratnesh K ^b   Babu, Jayaprakash ^a   Biswas, Sukla ^b   Rao, D N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

Author keywords

CpG ODN; Intranasal immunization; Microparticles; Peptide; Secretory component; Secretory IgA

Indexed keywords

ALUMINUM POTASSIUM SULFATE; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; CPG 1826; CPG 2006; GAMETOCYTE SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; MEMBRANE ANTIGEN; MEROZOITE SURFACE PROTEIN 1; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOPHELES STEPHENSI; ANTIBODY SPECIFICITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMODIUM VIVAX; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, PROTOZOAN; CPG ISLANDS; FEMALE; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULINS; MICE; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; PLASMODIUM VIVAX;

EID: 68949190996     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.06.008     Document Type: Article

References (66)

1. Sharma B.K., Talwar K.K., Bhatnagar V., Kumar L., Ganguly N.K., and Mahajan R.C. Recurrent anaphylaxis due to Plasmodium vivax infection. Lancet 1 (1979) 1340-1341
2. Plotkin S.L., and Plotkin S.A. Vaccines. In: Plotkin S.A., and Mortimer E.A. (Eds) (1988), W.B. Saunders, Philadelphia, Pa 1-7
3. Matuschewski K. Vaccine development against malaria. Curr Opin Immunol 18 (2006) 449-457
4. Good M.F., and Doolan D.L. Immune effector mechanisms in malaria. Curr Opin Immunol 11 (1999) 412-419
5. Herrera S., Corradin G., and Arevalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23 (2007) 122-128
6. Nussenzweig R.S., Vanderberg J.P., Most H., and Orton C. Specificity of protective immunity produced by x-irradiated Plasmodium berghei sporozoites. Nature 222 (1969) 488-489
7. Nussenzweig R.S., and Nussenzweig V. Antisporozoite vaccine for malaria: experimental basis and current status. Rev Infect Dis 11 (1989) 579-585
8. Nussenzweig V., and Nussenzweig R.S. Circumsporozoite proteins of malaria parasites. Cell 42 (1985) 401-403
9. Zavala F., Masuda A., Graves P.M., Nussenzweig V., and Nussenzweig R.S. Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol 35 (1985) 2790-2793
10. Pessi A., Michel M., Bianchi E., Mendis A., Tougne C., Verdini A.S., et al. Use of synthetic peptides in the study of the response to Plasmodium vivax sporozoites. Am J Trop Med Hyg 42 (1990) 17-23
11. Millet P., Chizzolini C., Wirtz R.A., Bathurst I., Broderson J.R., Campbell G.H., et al. Inhibitory activity against sporozoites induced by antibodies directed against nonrepititive regions of the circumsporozoite protein of Plasmodium vivax. Eur J Immunol 22 (1992) 519-524
12. Frevert U., Sinnis P., Cerami C., Shreffler W., Takacs B., and Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 177 (1993) 1287-1298
13. Bilsborough J., Baumgart K., Bathurst I., Barr P., and Good M.F. Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites. Acta Tropica 65 (1997) 59-80
14. Gibson H.L., Tucker J.E., Kaslow D.C., Krettli A.U., Collins W.E., Kiefer M.C., et al. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol Biochem Parasitol 50 (1992) 325-333
15. Waters A.P., Thomas A.W., Deans J.A., Mitchell G.H., Hudson D.E., Miller L.H., et al. A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium. J Biol Chem 265 (1990) 17974-17979
16. del Portillo H.A., Longacre S., Khouri E., and David P.H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci USA 88 (1991) 4030-4034
17. Putaporntip C., Jongwutiwes S., Sakihama N., Ferreira M.U., Kho W.G., Kaneko A., et al. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA 9 (2002) 16348-16353
18. Marcela P., George H., Armead H.J., Jay A.B., Theodore R., Isabella A.Q., et al. Characterization of conserved T- and B-cell epitopes in Plasmodium falciparum major merozoite surface protein1. Infect Immun 68 (2000) 2685-2691
19. Collins W.E., Pye D., Crewther P.E., Vandenberg K.L., Galland G.G., Sulzer A.J., et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51 (1994) 711-719
20. Triglia T., Healer J., Caruana S.R., Hodder A.N., Anders R.F., Crabb B.S., et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 38 (2000) 706-718
21. Narum D.L., and Thomas A.W. Differential localization of full length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67 (1994) 59-68
22. Snewin V.A., Premawansa S., Kapilananda G.M.G., Ratnayaka L., Udagama P.V., and Mattei D.M. Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J Exp Med 181 (1995) 357-362
23. Gordon D.M. Use of novel adjuvant and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens. Vaccine 11 (1993) 591-593
24. Bralolot-Millan C.L., Weeratna R., Kreig A.M., Siegrist C.A., and Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 95 (1998) 1555-1558
25. S. Kumar, T.R. Jones, M.S. Oakley, H. Zheng, S.P. Kuppusamy, A. Taye, et al., CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 2004; 72: 949-957.
26. Yi A.K., Klinman D.M., Martin T.L., Matson S., and Kreig A.M. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol 157 (1996) 5394-5402
27. Mullen G.E.D., Aebig J.A., Dobrescu G., Rausch K., Lambert L., Long C.A., et al. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 25 (2007) 5343-5347
28. Rosas J.E., Hernandez R.M., and Gascon A.R. Biodegradable PLGA microspheres as a delivery system for a malaria synthetic peptide SPf66. Vaccine 19 (2001) 4445-4451
29. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199 (2004) 201-216
30. Haneberg B., and Holst J. Can nonliving nasal vaccines be made to work?. Expert Rev Vaccines 1 (2002) 227-232
31. Harandi A.M., Sanchez J., Erikson K., and Holmgren J. Recent developments in mucosal immunomodulatory adjuvants. Curr Opin Investig Drugs 4 (2003) 156-161
32. Ogra P.I., Faden H., and Welliver R.C. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14 (2001) 430-445
33. Manocha M., Pal P.C., Chitralekha K.T., Thomas B.E., Tripathi V., Gupta S.D., et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as cell target. Vaccine 23 (2005) 5599-5617
34. Arakawa T., Tsuboi T., Kishimoto A., Sattabongkot J., Suwanabun N., Rungruang T., et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21 (2003) 3143-3148
35. Carcaboso A.M., Hernandez R.M., Igartua M., Rosas J.E., Patarroyo M.E., and Pedraz J.L. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22 (2004) 1423-1432
36. Hirunpetcharat C., Stanisic D., Liu X.Q., Vadolas J., Strugnell R.A., Lee R., et al. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP1 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol 20 (1998) 413-420
37. Bargieri D.Y., Rosa D.S., Lasaro M.A., Ferreira L.C., Soares I.S., and Rodrigues M.M. Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route. Mem Inst Oswaldo Cruz 102 3 (2007) 313-317
38. Bargieri D.Y., Rosa D.S., Lasaro M.A., Ferreira L.C., Soares I.S., and Rodrigues M.M. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein-1 and the TLR-5 agonist Salmonella typhimurium FliC flagellin. Vaccine 26 48 (2008) 6132-6142
39. Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., and Pedraz J.L. Influence of dose and immunization route on the serum IgG antibody response to BSA loaded PLGA microspheres. Vaccine 20 (2002) 2181-2190
40. Jeffery H., Davis S.S., and O'Hagan D.T. The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res 10 (1993) 362-368
41. Barman S.P., Lunsford L., Chambers P., and Hedley M.L. Two methods for quantifying DNA extracted from poly (lactide-co-glycolide) microspheres. J Control Release 69 (2000) 337-344
42. Mazier D., Mellouk S., and Beaudoin R.L. Effect of antibodies to recombinant and synthetic peptides of P. falciparum sporozoites in vitro. Science 231 (1986) 156-159
43. Rosas J.E., Pedraz J.L., and Hernandez R.M. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after one single immunization of SPf66 encapsulated in PLGA microspheres. Vaccine 20 (2002) 1707-1710
44. Salcedo M., Barreto L., Rojas M., Moya R., Cote J., and Patarroyo M.E. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 84 (1991) 122-128
45. Coban C., Ishii K.J., Stowers A.W., Keister D.B., Klinman D.M., and Kumar N. Effect of CpG oligodexynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun 72 (2004) 584-588
46. Brandtzaeg P., Baklein K., Rognum T.O., Scott H., and Valnes K. Nature and properties of the human gastrointestinal immune system. In: Miller K., and Nicklin S. (Eds). Immunology of the gastrointestinal tract (1987), CRC Press, Boca Raton, FL 1-85
47. Mazzoli S., Trabattoni D.L., Caputo S., Piconi S., Blé C., Meacci F., et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3 (1997) 1250-1257
48. Philapon A., Cardona A., Kraehenbuhl J.P., Edelman L., Sansonetti P.J., and Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 17 (2002) 107-115
49. Phillips-Quagliata J.M., and Lamm M.E. Lymphocyte homing to mucosal effector sites. In: Ogra P.L., Strober W., Mestecky J., McGhee J.R., Lamm M.E., and Bienenstock J. (Eds). Handbook of mucosal immunology (1994), Academic Press, San Diego CA 225-239
50. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J.P., and Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun 62 (1994) 15-23
51. Gallichan W.S., and Rosenthal K.L. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 13 (1995) 1589-1595
52. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161 (1998) 4463-4469
53. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
54. Bomford R., Stapleton M., Winsor S., Mcknight A., and Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retrov 8 (1992) 1765-1771
55. Eldridge J.H., Hammond C.J., Meulbroek J.A., Stass J.K., Gilley R.W., and Tice T.R. Controlled vaccine released in the gut-associated lymphoid tissue. Orally administered biodegradable microspheres target the peyer's patches. J Control Release 11 (1990) 205-214
56. Aguado M.T., and Lambert P.H. Controlled release vaccines-biodegradable polylactide/glycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 184 (1992) 113-125
57. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
58. Manzel L., and Macfarlane D.E. Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev 9 (1999) 459-464
59. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17 (1999) 3065-3071
60. Arevalo-Herrera M., Roggero M.A., Gonzalez J.M., Vergara J., Corradin G., Lopez J.A., et al. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys. Ann Trop Med Parasitol 92 (1998) 539-551
61. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93 (1996) 2879-2883
62. Davila E., and Celis E. Repeated administration of cytosine-phosphorothioated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165 (2000) 539-547
63. McCluskie M.J., and Davis H.L. Oral, intrarectal and intranasal immunization using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19 (2001) 413-422
64. Davis H.L., Weeratna R.R., Jumintarto, Chamzah S.S., Iskandriati D.D., Ma'ruf A.A., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18 (2000) 1920-1924
65. Hisaeda H., Stowers A.W., Tsuboi T., Collins W.E., Sattabongkot J.S., Suwanabun N., et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 (2000) 6618-6623
66. Anders R.F., Crewther P.E., Edwards S., Margetts M., Mathew M.L.S.M., Pollock B., et al. Immunization with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 (1998) 240-247